Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DNA X, Inc. filings document the company's shift from Sonim Technologies to a cryptocurrency trading-services business, including the acquisition of DNA X LLC, the completed sale of mobile device assets, and the January 2026 corporate rebrand while the Nasdaq ticker remained SONM.
The filing record includes Current Reports on Form 8-K and related amendments covering material agreements, convertible-note financing, common-stock issuance, operating results, shareholder voting matters, executive departures and compensation arrangements, and auditor changes. Other disclosures address late annual-report notification, internal-control weakness, going-concern language, capital structure, risk factors, and financial-reporting obligations.
DNA X, Inc. amended a prior report to detail a preferred stock financing that improves its stockholders’ equity and supports continued listing on the Nasdaq Capital Market.
On July 8, 2026 the company sold 929,864 shares of Series B Preferred Stock for $2.5 million in cash and cancellation of $3.1 million of a convertible note, and expects to issue another 416,667 shares by August 14, 2026. A pro forma table shows stockholders’ equity moving from deficits in Q1 2026 and estimated Q2 2026 to an estimated $3.8 million as of July 9, 2026, above Nasdaq’s $2.5 million equity requirement, while the company awaits Nasdaq’s formal compliance determination.
DNA X, Inc. entered into a private placement with major holder DNA Holdings Venture to issue 1,346,531 shares of non-voting Series B Convertible Preferred Stock at $6.00 per share, for an aggregate $8.1 million consisting of $5.0 million in cash and cancellation of $3.1 million of note principal.
The Series B Preferred will automatically convert into Common Stock after stockholder approval at an initial conversion price equal to the $6.00 stated value, with customary anti-dilution adjustments and registration rights for resale of the underlying shares. The preferred stock has no general voting rights, a 1x liquidation preference and is not redeemable.
DNA Holdings receives preemptive rights to participate in future financings for 12 months, capped at 50% of each deal. At closing, DNA X also expects to enter a consulting agreement with DNA Holdings, Scott Walker and Brock Pierce, providing 2,494,000 shares of Common Stock as equity consideration, subject to stockholder approval.
DNA X, Inc. files a post-effective amendment to deregister 350,000,000 shares of common stock previously registered for resale by Chardan Capital Markets, LLC.
The amendment states all offerings under Form S-1 (File No. 333-290589) have been terminated and the registrant removes from registration any registered but unsold or unissued securities as of June 8, 2026.
DNA X, Inc. terminated its financing arrangements with Chardan Capital Markets LLC that had allowed Chardan to purchase up to $500 million of DNA X common stock. These arrangements consisted of a ChEF Purchase Agreement and a related Registration Rights Agreement.
The termination was effected by letter agreement and became effective as of 5:00 p.m. New York City time on May 28, 2026. These agreements had previously given Chardan the ability to buy shares over time and required DNA X to register those shares for resale.
DNA X, Inc. entered a Securities Purchase Agreement with DNA Holdings Venture, Inc. and issued a secured convertible promissory note with principal of $3,052,787.68. The company received $1,800,000.00 in cash and cancelled a prior $1,200,000.00 note plus accrued interest.
The new note matures on December 31, 2026, bears 10% annual interest, and is convertible into common stock at $6.00 per share, subject to stockholder approval and adjustment. Proceeds must be used for working capital, excluding repayment of most debt, equity redemptions, or litigation settlements.
The company also amended a Membership Interest Purchase Agreement to terminate a put option and secured the note with a first-priority lien on its ownership interests in DNA X, LLC. Separately, Nasdaq staff issued a delisting determination after the company reported a stockholders’ deficit of $983,000 versus the $2,500,000 stockholders’ equity requirement. DNA X plans to request a hearing, but there is no assurance it will regain or maintain Nasdaq listing compliance.
DNA X, Inc. (formerly Sonim Technologies) has completed a major strategic shift and now focuses on its DNA X AI and crypto trading platform after selling its legacy phone and hotspot business. The January 23, 2026 asset sale generated a pre-tax gain of $15,563 thousand and net income from discontinued operations of $10,268 thousand for the quarter, driving total net income to $6,340 thousand despite no revenue from continuing operations and a continuing-operations net loss of $3,928 thousand.
Total assets dropped to $4,838 thousand at March 31, 2026 from $43,898 thousand after removing the disposed business, while stockholders’ deficit narrowed to $983 thousand. Cash and cash equivalents were $1,195 thousand, and the company carries a related-party convertible note with a principal of $1,200 thousand plus a derivative liability of $398 thousand tied to its conversion features.
On May 20, 2026, DNA X issued a new related-party convertible promissory note with a principal balance of $3,053 thousand, receiving $1,800 thousand in cash and cancelling the prior note and accrued interest. Management states these proceeds are expected to fund operation of the AI and crypto platform through December 31, 2026, but also discloses substantial doubt about the company’s ability to continue as a going concern if the note is not converted or additional financing is not obtained.
DNA X, Inc. reported first-quarter 2026 results that reflect its exit from the legacy mobile device business and pivot to an AI-driven crypto trading platform. The company sold its mobile device design and manufacturing assets to NEXA for $15 million, less a $1.5 million working capital adjustment, generating $6.3 million in net income from the sale.
From continuing operations, DNA X recorded a $3.9 million net loss as it invested in the DNA X AI trading platform, while revenue from phones and hotspots is now reported in discontinued operations. Cash was $1.2 million at March 31, 2026, and the company agreed to raise an additional $1.8 million through new debt to fund working capital and support growth of the AI and crypto trading business.
DNA X, Inc. notified the SEC that it could not timely file its Form 10-Q for the three months ended March 31, 2026. The delay stems from the disposition of the company’s Legacy Business and the required discontinued operations accounting under ASC 205-20, which requires separating current results, retrospectively recasting prior periods, and computing the gain or loss on disposition and related income-tax allocation.
The company says the accounting complexity and the need for accurate retrospective adjustments have extended the financial close. DNA X expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date and anticipates reporting $3.6 million net loss from continuing operations for the three months ended March 31, 2026, compared to $0.7 million net loss for the three months ended March 31, 2025.
DNA X, Inc. ownership filing: Laurence W. Lytton reports beneficial ownership of 120,357 shares of Common Stock, representing 8.1% of the class. The percentage is calculated based on 1,488,268 shares outstanding as of April 21, 2026. The filing notes that this total excludes warrants to purchase 22,222 shares that are subject to a 4.99% beneficial ownership limitation.